More and more cancer patients get chemoport implants rather than get injections repeatedly on peripheral blood vessels, as cancer drugs sometimes damage the small vessels and the surrounding tissue. A chemoport is the most reliable and convenient method of central venous access. MEDITULIP developed TULIP PORT, a chemoport to maximize patient comfort and safety by making the housing thin and small and the septum wide yet pressure-resistant. TULIP PORT is power-injectable and supports X-ray, CT and MRI examinations. Moreover, MEDITULIP uses more expensive, implantable-grade polysulfone material. MEDITULIP received regulatory approval in South Korea and is preparing for regulatory approval of its chemoports in other countries.